Michael J Pontecorvo

List of Publications by Year
in descending order

28 papers	5,116 citations	304743 22 h-index	552781 26 g-index
30 all docs	30 docs citations	30 times ranked	5175 citing authors

#	Article	IF	Citations
1	Use of Florbetapir-PET for Imaging β-Amyloid Pathology. JAMA - Journal of the American Medical Association, 2011, 305, 275.	7.4	927
2	Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurology, The, 2012, 11, 669-678.	10.2	674
3	In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ^{18}F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine, 2010, 51, 913-920.	5.0	607
4	Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nature Medicine, 2021, 27, 871-881.	30.7	354
5	Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. Journal of Nuclear Medicine, 2012, 53, 378-384.	5.0	321
6	Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Annals of Neurology, 2013, 74, 826-836.	5.3	320
7	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain, 2017, 140, aww334.	7.6	257
8	Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurology, 2020, 77, 829.	9.0	244
9	Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology, 2012, 79, 1636-1644.	1.1	206
10	Tau Positron-Emission Tomography in Former National Football League Players. New England Journal of Medicine, 2019, 380, 1716-1725.	27.0	165
11	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. Brain, 2019, 142, 1723-1735.	7.6	156
12	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 4.	6.2	134
13	In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with ^{18}F-AV-133. Journal of Nuclear Medicine, 2010, 51, 223-228.	5.0	122
14	Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiology of Aging, 2013, 34, 822-831.	3.1	118
15	Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. Alzheimer Disease and Associated Disorders, 2013, 27, 4-15.	1.3	109
16	Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity. Journal of Nuclear Medicine, 2018, 59, 944-951.	5.0	73
17	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	7.6	65
18	A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. Journal of Nuclear Medicine, 2015, 56, 1736-1741.	5.0	61

#	Article	IF	Citations
19	^{18}F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. Journal of Nuclear Medicine, 2015, 56, 386-391.	5.0	41
20	Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 825-837.	6.4	40
21	PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 11.	6.2	34
22	Quantification of 18F-florbetapir PET: comparison of two analysis methods. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 725-732.	6.4	25
23	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. EJNMMI Research, 2020, 10, 65.	2.5	25
24	Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. Journal of Alzheimer's Disease, 2021, 80, 1091-1104.	2.6	17
25	Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease. Annals of Nuclear Medicine, 2015, 29, 570-581.	2.2	10
26	DT-02-03: A randomized, controlled, multicenter, international study of the impact of florbetapir (18) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		3
27	Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy. Journal of Neuropathology and Experimental Neurology, 2022, 81, 158-171.	1.7	2
28	Methods and future directions for evaluation of Tau PET signal. Alzheimer's and Dementia, 2021, 17, .	0.8	0